Decoding the complexity of type I interferon to treat persistent viral infections

Trends in Microbiology

Volumn 21, Issue 12, 2013, Pages 634-640

  Wilson, Elizabeth B ^a   Brooks, David G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HIV; Immune activation; Immunosuppression; LCMV; Persistent; Therapy; Type I interferon; Virus

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; ALPHA2A INTERFERON; BETA INTERFERON; BETA INTERFERON RECEPTOR; INTERFERON; INTERFERON ANTIBODY; JANUS KINASE; JANUS KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE; MYXOVIRUS RESISTANCE PROTEIN; PEGINTERFERON ALPHA2B; PEGINTERFERON BETA1A; PROTEIN KINASE R; PROTEIN KINASE TYK2; RIBAVIRIN; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN;

ANGIOGENESIS; ANTIVIRAL ACTIVITY; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DRUG EFFICACY; ENZYME ACTIVATION; EPISTAXIS; GENE; GENE EXPRESSION PROFILING; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; INTERFERON STIMULATED GENE; LEUKEMIA; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MELANOMA; METASTASIS; MULTIPLE SCLEROSIS; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RESPIRATORY TRACT INFECTION; REVIEW; SIGNAL TRANSDUCTION; TH2 CELL; TUMOR GROWTH; VIRUS CARCINOGENESIS; VIRUS INHIBITION; VIRUS REPLICATION;

LYMPHOCYTIC CHORIOMENINGITIS VIRUS;

HIV; IMMUNE ACTIVATION; IMMUNOSUPPRESSION; LCMV; PERSISTENT; THERAPY; TYPE I INTERFERON; VIRUS;

ANIMALS; HUMANS; INTERFERON TYPE I; VIRUS DISEASES; VIRUS PHYSIOLOGICAL PHENOMENA; VIRUSES;

EID: 84888862802     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2013.10.003     Document Type: Review

References (73)

1. Stetson D.B., Medzhitov R. Type I interferons in host defense. Immunity 2006, 25:373-381.
2. Yoneyama M., et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 2004, 5:730-737.
3. Kato H., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006, 441:101-105.
4. Honda K., et al. Type I interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006, 25:349-360.
5. Pestka S., et al. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 2004, 202:8-32.
6. de Weerd N.A., et al. Type I interferon receptors: biochemistry and biological functions. J. Biol. Chem. 2007, 282:20053-20057.
7. Jaks E., et al. Differential receptor subunit affinities of type I interferons govern differential signal activation. J. Mol. Biol. 2007, 366:525-539.
8. de Weerd N.A., et al. Structural basis of a unique interferon-beta signaling axis mediated via the receptor IFNAR1. Nat. Immunol. 2013, 14:901-907.
9. Darnell J.E., et al. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
10. Torpey N., et al. Interferon alpha but not interleukin 12 activates STAT4 signaling in human vascular endothelial cells. J. Biol. Chem. 2004, 279:26789-26796.
11. Farrar J.D., et al. Recruitment of Stat4 to the human interferon-alpha/beta receptor requires activated Stat2. J. Biol. Chem. 2000, 275:2693-2697.
12. Honda K., Taniguchi T. Toll-like receptor signaling and IRF transcription factors. IUBMB Life 2006, 58:290-295.
13. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 2005, 5:375-386.
14. Liu S.Y., et al. Systematic identification of type I and type II interferon-induced antiviral factors. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:4239-4244.
15. Schoggins J.W., et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472:481-485.
16. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B: Biol. Sci. 1957, 147:258-267.
17. Haller O., et al. Interferon, Mx, and viral countermeasures. Cytokine Growth Factor Rev. 2007, 18:425-433.
18. Garcia M.A., et al. The dsRNA protein kinase PKR: virus and cell control. Biochimie 2007, 89:799-811.
19. Silverman R.H. Fascination with 2-5A-dependent RNase: a unique enzyme that functions in interferon action. J. Interferon Res. 1994, 14:101-104.
20. Sarasin-Filipowicz M., et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7034-7039.
21. Bosinger S.E., et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J. Clin. Invest. 2009, 119:3556-3572.
22. Baechler E.C., et al. Gene expression profiling in human autoimmunity. Immunol. Rev. 2006, 210:120-137.
23. Zhou A., et al. Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways. Virology 1999, 258:435-440.
24. Biron C.A. Initial and innate responses to viral infections-pattern setting in immunity or disease. Curr. Opin. Microbiol. 1999, 2:374-381.
25. Welsh R.M., et al. Type 1 interferons and antiviral CD8 T-cell responses. PLoS Pathog. 2012, 8:e1002352.
26. Havenar-Daughton C., et al. Cutting edge: the direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J. Immunol. 2006, 176:3315-3319.
27. Kolumam G.A., et al. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 2005, 202:637-650.
28. Carbonneil C., et al. Dendritic cells generated in the presence of granulocyte-macrophage colony-stimulating factor and IFN-alpha are potent inducers of HIV-specific CD8 T cells. AIDS 2003, 17:1731-1740.
29. Le Bon A., et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol. 2003, 4:1009-1015.
30. Gonzalez-Navajas J.M., et al. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 2012, 12:125-135.
31. Arimori Y., et al. Type I interferon limits influenza virus-induced acute lung injury by regulation of excessive inflammation in mice. Antiviral Res. 2013, 99:230-237.
32. Schreiner B., et al. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J. Neuroimmunol. 2004, 155:172-182.
33. Rudick R.A., et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997. Neurology 2001, 57:S25-S30.
34. McBride J.M., et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 2012, 64:3666-3676.
35. Wang B., et al. Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-alpha receptor antibody. Clin. Pharmacol. Ther. 2013, 93:483-492.
36. Higgins P.G., et al. The efficacy of intranasal interferon alpha-2a in respiratory syncytial virus infection in volunteers. Antiviral Res. 1990, 14:3-10.
37. Scott G.M., et al. Purified interferon as protection against rhinovirus infection. Br. Med. J. (Clin. Res. Ed.) 1982, 284:1822-1825.
38. Heim M.H. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat. Rev. Immunol. 2013, 13:535-542.
39. Chen L., et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005, 128:1437-1444.
40. Azzoni L., et al. Pegylated interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J. Infect. Dis. 2013, 207:213-222.
41. Sauce D., et al. Monitoring cellular immune markers in HIV infection: from activation to exhaustion. Curr. Opin. HIV AIDS 2013, 8:125-131.
42. Asmuth D.M., et al. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J. Infect. Dis. 2010, 201:1686-1696.
43. Tarhini A.A., Kirkwood J.M. Clinical and immunologic basis of interferon therapy in melanoma. Ann. N. Y. Acad. Sci. 2009, 1182:47-57.
44. Hervas-Stubbs S., et al. Direct effects of type I interferons on cells of the immune system. Clin. Cancer Res. 2011, 17:2619-2627.
45. Burnette B.C., et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 2011, 71:2488-2496.
46. Tarhini A.A., et al. IFN-alpha in the treatment of melanoma. J. Immunol. 2012, 189:3789-3793.
47. Avolio C., et al. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult. Scler. 2005, 11:441-446.
48. Guarda G., et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011, 34:213-223.
49. Wang X., et al. IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis. J. Immunol. 2000, 165:548-557.
50. Gold R., et al. Evolving expectations around early management of multiple sclerosis. Ther. Adv. Neurol. Disord. 2010, 3:351-367.
51. Teijaro J.R., et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013, 340:207-211.
52. Wilson E.B., et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013, 340:202-207.
53. Wilson E.B., et al. Emergence of distinct multiarmed immunoregulatory antigen-presenting cells during persistent viral infection. Cell Host Microbe 2012, 11:481-491.
54. Ng C.T., Oldstone M.B. Infected CD8alpha-dendritic cells are the predominant source of IL-10 during establishment of persistent viral infection. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:14116-14121.
55. Muller U., et al. Functional role of type I and type II interferons in antiviral defense. Science 1994, 264:1918-1921.
56. Wang Y., et al. Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. Cell Host Microbe 2012, 11:631-642.
57. Lee M.S., et al. Negative regulation of type I IFN expression by OASL1 permits chronic viral infection and CD8(+) T-cell exhaustion. PLoS Pathog. 2013, 9:e1003478.
58. Cervantes-Barragan L., et al. Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon. Blood 2007, 109:1131-1137.
59. Klatt N.R., et al. Microbial translocation, immune activation, and HIV disease. Trends Microbiol. 2013, 21:6-13.
60. Boasso A., Shearer G.M. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin. Immunol. 2008, 126:235-242.
61. Moir S., et al. Pathogenic mechanisms of HIV disease. Annu. Rev. Pathol. 2011, 6:223-248.
62. Hosmalin A., Lebon P. Type I interferon production in HIV-infected patients. J. Leukoc. Biol. 2006, 80:984-993.
63. Jacquelin B., et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J. Clin. Invest. 2009, 119:3544-3555.
64. Estes J.D., et al. Early resolution of acute immune activation and induction of PD-1 in SIV-infected sooty mangabeys distinguishes nonpathogenic from pathogenic infection in rhesus macaques. J. Immunol. 2008, 180:6798-6807.
65. Hyrcza M.D., et al. Distinct transcriptional profiles in ex vivo CD4+ and CD8+ T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD8+ T cells. J. Virol. 2007, 81:3477-3486.
66. Murray S.M., et al. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J. Virol. 2010, 84:12082-12086.
67. Paton N.I., et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA 2012, 308:353-361.
68. Martinson J.A., et al. Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrob. Agents Chemother. 2010, 54:871-881.
69. Piconi S., et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 2011, 118:3263-3272.
70. Gringeri A., et al. Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1996, 13:55-67.
71. Ries M., et al. Blocking type I interferon production: a new therapeutic option to reduce the HIV-1-induced immune activation. Clin. Dev. Immunol. 2012, 2012:534929.
72. Merrill J.T., et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann. Rheum. Dis. 2011, 70:1905-1913.
73. Wang B., et al. Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-α receptor antibody. Clin. Pharmacol. Ther. 2013, 93:483-492.